Results 51 to 60 of about 3,014 (182)

Supplementary Figure 5 from Resistance to Selective FGFR Inhibitors in FGFR-Driven Urothelial Cancer

, 2023
Synergic effect of gefitinib and erdafitinib in MR15 cell line.
Rastislav Bahleda (16617234), Giorgia Guaitoli (16827105), Francesco Facchinetti (16827090), David Combarel (16827111), Stefan Michiels (9081965), Antoine Hollebecque (15010338), Yoann Pradat (15352227), Santiago Ponce-Aix (16827114), Sergey I. Nikolaev (15061686), Luc Friboulet (15025943), Lambros Tselikas (15019536), Ludovic Bigot (16617254), Juan David Florez Arango (16827102), Hayato Mizuta (16827108), Benjamin Besse (15061674), Damien Vasseur (16827096), Cédric Pobel (16617263), Olivier Déas (16827099), Floriane Braye (16827093), Ken A. Olaussen (16827117), Yohann Loriot (15123021), Jean-Yves Scoazec (15036392)   +21 more
core   +2 more sources

Covalent drug discovery: Progress against key targets, emerging strategies and lessons learnt

British Journal of Pharmacology, Volume 183, Issue 22, Page 6574-6606, November 2026.
Abstract Covalent drug discovery is currently experiencing a boom in industrial and academic interest. To date, at least 75 covalent drugs have received regulatory approval, targeting both traditional target classes and more challenging proteins for which other approaches failed. In many cases, unique aspects of covalent targeting are essential for the
Charles P. Brown, Alan Armstrong, David J. Mann   +2 more
wiley   +1 more source

Figure S2 from Multicenter Phase I Study of Erdafitinib (JNJ-42756493), Oral Pan-Fibroblast Growth Factor Receptor Inhibitor, in Patients with Advanced or Refractory Solid Tumors

, 2019
Supplementary Figure S2. Model-predicted and observed serum phosphate concentrations vs erdafitinib plasma concentrations (left panel: total erdafitinib concentrations; right panel: unbound erdafitinib concentrations). Continuous and dashed lines: median
Alain Mita (6295982), Alexander Spira (11395472), Ramaswamy Govindan (60360), Martha Gonzalez (3638434), Mark Awad (6525626), Trilok Parekh (15018212), Italo Poggesi (2396347), Jeffrey Infante (3816376), Josep Tabernero (237681), Bob Zhong (15018209), Rastislav Bahleda (13011628), Ademi Santiago-Walker (15001046), Victor Moreno (748751), Hong Xie (133048), Emiliano Calvo (6271580), Andres Cervantes (8456292), Cinta Hierro (15018206), Antoine Italiano (725114), Nancy Chan (6727526)   +18 more
core   +1 more source

Tackling FGFR3-driven bladder cancer with a promising synergistic FGFR/HDAC targeted therapy

npj Precision Oncology, 2023
Bladder cancer (BC) is one of the most prevalent malignancies worldwide and FGFR3 alterations are particularly common in BC. Despite approval of erdafitinib, durable responses for FGFR inhibitors are still uncommon and most patients relapse to metastatic
Zechen Wang, Viswanathan Muthusamy, Daniel P. Petrylak, Karen S. Anderson   +3 more
doaj   +1 more source

Next‐Generation Sequencing‐Based Molecular Profiling and Management of Advanced Solid Tumors: A Real‐World Experience in a Community‐Based Academic Cancer Center

Cancer Medicine, Volume 15, Issue 10, October 2026.
ABSTRACT Background Advances in molecular and cell biology have led to a paradigm shift in cancer management. We implemented next‐generation sequencing (NGS) at our community‐based academic cancer center over a decade ago. We sought to optimize the use of genomics and understand its impact in identifying actionable genomic alterations to determine ...
Gayathri Moorthy, Annette Sereika, Karen Kaul, Megan Parilla, Mir B. Alikhan, Michael Bouma, Dyson Wake, Peter J. Hulick, Henry M. Dunnenberger, Linda M. Sabatini, Mathew Yang, Kathy A. Mangold, Erin Proctor, Nicholas Evans, Nicholas Miller, Donald L. Helseth Jr, Darryck Maurer, Justin Brueck, Janardan Khandekar, Bruce Brockstein   +19 more
wiley   +1 more source

Characterizing ADRs of Enfortumab vedotin and Erdafitinib in bladder cancer treatment: a descriptive analysis from WHO-VigiAccess

Frontiers in Pharmacology
IntroductionEnfortumab vedotin (EV) and Erdafitinib are effective therapeutic drugs for bladder cancer patients following post-chemotherapy and immunotherapy.
Yuanbin Huang, Meiqi Xu, Xinmiao Ma, Wei Wang, Chen Shen, Fei Liu, Zhiqi Chen, Jiawen Wang, Qian Guo, Xiancheng Li   +9 more
doaj   +1 more source

Current and Emerging Treatments for Urothelial Carcinoma: A Focus on Enfortumab Vedotin

Cancer Management and Research, 2023
Muhammad Ashir Shafique, Abdul Haseeb, Mohammad Arham Siddiq, Abdullah Mussarat, Hussain Sohail Rangwala, Muhammad Saqlain Mustafa Department of Medicine, Jinnah Sindh Medical University, Karachi, PakistanCorrespondence: Muhammad Ashir Shafique ...
Shafique MA, Haseeb A, Siddiq MA, Mussarat A, Rangwala HS, Mustafa MS   +5 more
doaj  

Patient‐Derived Organoids in Functional Precision Oncology: Tumor Modeling, Drug‐Response Prediction, and Clinical Translation

Cell Biochemistry and Function, Volume 44, Issue 10, October 2026.
ABSTRACT Patient‐derived organoids (PDOs) have emerged as an effective experimental platform for bridging the long‐standing gap between traditional in vitro cancer models and the biological complexity of actual tumors. These three‐dimensional cultures (3D), derived directly from patient tissues, preserve essential architectural, genomic, and phenotypic
Abdullah Jabri, Mohamed Alsharif, Abdulaziz Mhannayeh, Bader Taftafa, Dania Sibai, Abdulrahman Elsalti, Raghad Alsharif, Tanveer Ahmad Mir, Mohammed Imran Khan, Jahan Salma, Ahmed Yaqinuddin   +10 more
wiley   +1 more source

Oncogenic Characterization and Pharmacologic Sensitivity of Activating Fibroblast Growth Factor Receptor (FGFR) Genetic Alterations to the Selective FGFR Inhibitor Erdafitinib

, 2017
Fibroblast growth factor receptor (FGFR) genetic alterations are frequently observed in cancer, suggesting that FGFR inhibition may be a promising therapy in patients harboring these lesions. Identification of predictive and pharmacodynamic biomarkers to
Michael Sharp, Katherine Bell, Ademi Santiago-Walker, Feng R. Luo, Gabriela Martinez Cardona, Suso J. Platero, Jayaprakash D. Karkera, John D. Alvarez, Rastislav Bahleda, Peter King, Matthew V. Lorenzi, Joseph C. Portale, Christopher H. Moy, Dana Gaffney   +13 more
core   +1 more source

Neuro‐associated SEMA3C+ tumour cells promote gastric cancer peritoneal metastasis via EBF2–FGF7–FGFR2‐mediated tumour–endothelial crosstalk

Clinical and Translational Medicine, Volume 16, Issue 10, October 2026.
Single‐nucleus sequencing identified a semaphorin 3C (SEMA3C)‐high stem‐like tumour subpopulation that drives gastric cancer peritoneal metastasis through early B‐cell factor 2 (EBF2)‐mediated FGF7 expression and enhanced FGF7–FGFR2 signalling with endothelial cells. Targeting the FGF–FGFR pathway may provide a promising therapeutic strategy.
Yajing Zhou, Chao Dong, Weikang Li, Minghao Sun, Qingyu Xie, Lixing Gu, Pengbo Wang, Chengxiang Xu, Tianzhan Gao, Caixin Zhu, Kaipeng Duan, Jin Zhou, Dongbao Li   +12 more
wiley   +1 more source